Multiple Sclerosis Clinical Trial
— MStepOfficial title:
The Role of Exercise in Modifying Outcomes for People With Multiple Sclerosis
Verified date | April 2017 |
Source | McGill University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Despite the benefits of exercise and physical activity people with Multiple Sclerosis (MS)
are relatively inactive. Physical activity is important for persons with disabilities to
maintain physical function. A lack of physical activity can contribute to heart disease,
osteoporosis, obesity, and diabetes. At the moment, the best way for people with MS to
exercise and be physical activity is unknown. People with MS report not knowing what to do.
This is a barrier to exercise.
The global aim of this study is to contribute evidence for the role of targeted exercise in
altering MS outcomes over time. The design is a randomized controlled trial (RCT). The
primary research question is to what extent does an MS Tailored Exercise Program (MSTEP)
result in greater improvements in exercise capacity and related outcomes in comparison to a
program based on general guidelines for exercise among people with MS who are sedentary and
wish to engage in exercise as part of MS self-management. The primary outcome for this
question is exercise capacity measured using cycle ergometry. However exercise efficiency,
functional ambulation, strength, components of quality of life including frequency and
intensity of fatigue symptoms, mood, global physical function, health perception, and
illness intrusiveness, will also be measured as components of a global response outcome. The
first confirmatory hypothesis is that MSTEP will result in a greater proportion of people
making clinically relevant gains (at least 10% change) in exercise capacity than with
general guidelines after 12 months of intervention; a secondary hypothesis is that, while
there may be some decline in exercise capacity among individuals from end of intervention to
follow-up one year later, the decline will be greater in the general guideline group
augmenting the difference between groups in the proportion making 10% change from study
entry to 24 months. In other words, gains will be maintained more for the MSTEP group over
the general guideline group.
An exploratory hypothesis is that more of the targeted outcomes will improve with the MSTEP
program than the general guideline approach. An explanatory hypothesis is that these gains
will be accompanied by reports of greater exercise enjoyment and exercise self-efficacy
(confidence) with the MSTEP program than with the general guideline program leading to more
consistent exercise engagement and improved long-term adherence.
Status | Active, not recruiting |
Enrollment | 240 |
Est. completion date | December 2018 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years to 65 Years |
Eligibility |
Inclusion Criteria: - be community dwelling individuals aged 19 -65 who have been diagnosed after 1994 with MS or CIS; - be able to speak and read English or French; - be capable of walking 100 meters without a walking aid (EDSS = 5.5), even if they do use an aid for daily activities. Exclusion Criteria: - have an additional illness that restricts their function; and/or - had suffered at least one relapse during the past 30 days (as defined by Polman) as this may affect physical activity/exercise participation. |
Country | Name | City | State |
---|---|---|---|
Canada | CHUM | Montreal | Quebec |
Canada | Muhc - Mnh | Montreal | Quebec |
Canada | St. Michael's Hospital | Toronto | Ontario |
Canada | Sunnybrook Hospital | Toronto | Ontario |
Canada | Toronto Rehabiliation Institute | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
McGill University |
Canada,
Asano M, Dawes DJ, Arafah A, Moriello C, Mayo NE. What does a structured review of the effectiveness of exercise interventions for persons with multiple sclerosis tell us about the challenges of designing trials? Mult Scler. 2009 Apr;15(4):412-21. doi: 10.1177/1352458508101877. Review. Erratum in: Mult Scler. 2016 Oct;22(11):NP4. — View Citation
Dalgas U, Stenager E, Ingemann-Hansen T. Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training. Mult Scler. 2008 Jan;14(1):35-53. Epub 2007 Sep 19. Review. — View Citation
Dalgas U, Stenager E, Jakobsen J, Petersen T, Hansen HJ, Knudsen C, Overgaard K, Ingemann-Hansen T. Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology. 2009 Nov 3;73(18):1478-84. doi: 10.1212/WNL.0b013e3181bf98b4. — View Citation
Hayes HA, Gappmaier E, LaStayo PC. Effects of high-intensity resistance training on strength, mobility, balance, and fatigue in individuals with multiple sclerosis: a randomized controlled trial. J Neurol Phys Ther. 2011 Mar;35(1):2-10. doi: 10.1097/NPT.0b013e31820b5a9d. — View Citation
Mayo N. Setting the agenda for multiple sclerosis rehabilitation research. Mult Scler. 2008 Nov;14(9):1154-6. doi: 10.1177/1352458508096567. — View Citation
Motl RW, McAuley E, Snook EM. Physical activity and multiple sclerosis: a meta-analysis. Mult Scler. 2005 Aug;11(4):459-63. — View Citation
Motl RW, Snook EM, McAuley E, Gliottoni RC. Symptoms, self-efficacy, and physical activity among individuals with multiple sclerosis. Res Nurs Health. 2006 Dec;29(6):597-606. — View Citation
Poppe AY, Wolfson C, Zhu B. Prevalence of multiple sclerosis in Canada: a systematic review. Can J Neurol Sci. 2008 Nov;35(5):593-601. — View Citation
Rietberg MB, Brooks D, Uitdehaag BM, Kwakkel G. Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003980. Review. — View Citation
Turner AP, Kivlahan DR, Haselkorn JK. Exercise and quality of life among people with multiple sclerosis: looking beyond physical functioning to mental health and participation in life. Arch Phys Med Rehabil. 2009 Mar;90(3):420-8. doi: 10.1016/j.apmr.2008.09.558. — View Citation
Warren S, Warren KG, Svenson LW, Schopflocher DP, Jones A. Geographic and temporal distribution of mortality rates for multiple sclerosis in Canada, 1965-1994. Neuroepidemiology. 2003 Jan-Feb;22(1):75-81. — View Citation
Warren S, Warren KG. Prevalence, incidence, and characteristics of multiple sclerosis in Westlock County, Alberta, Canada. Neurology. 1993 Sep;43(9):1760-3. — View Citation
White LJ, Castellano V. Exercise and brain health--implications for multiple sclerosis: Part 1--neuronal growth factors. Sports Med. 2008;38(2):91-100. Review. — View Citation
White LJ, Castellano V. Exercise and brain health--implications for multiple sclerosis: Part II--immune factors and stress hormones. Sports Med. 2008;38(3):179-86. Review. — View Citation
* Note: There are 14 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | oxygen consumption | VO2peak will be determined using an incremental graded cycle ergometer test. Greater oxygen consumption implies in better exercise capacity | 3 timepoints: baseline, at 12 monts, at 24 months | |
Secondary | muscle strength measured with Biodex | Greater values imply greater muscle strength | 3 timepoints: Baseline, at 12 months, at 24 months | |
Secondary | 6 Minute Walk test (6MWT) | Distance walked will be measured with the 6-Minute Walk Test. Greater values imply that a longer distance was covered within 6 minutes | 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months | |
Secondary | Anaerobic leg power | Greater value indicate greater anaerobic leg power | 1 timepoint: baseline | |
Secondary | Patient Determined Disease Steps (PDDS) | Patient Determined Disease Steps (PDDS) is a scale focusing mainly on how well someone walk. It ranges from mild symptoms that do not affect physical activity to inability to sit in a wheel chair for more than 1 hour. | 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months | |
Secondary | Change in fatigue levels | Fatigue will be measured with a single item question asking them the number of days that they felt certain levels of fatigue. | 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months | |
Secondary | Rand 36 | Health status will be measured with the Rand36 Health Status Survey. The Rand36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. | 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months | |
Secondary | EQ-5D | The respondent is asked to indicate his/her health state in each of 5 dimensions. The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state.The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. This information can be used as a quantitative measure of health as judged by the individual respondents | 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months | |
Secondary | Patient generated Index | Participants will be asked to identify 5 most important areas of their life that are affected by multiple sclerosis. A second step will be to score how much affected these identified areas were over the past MONTH, in a scale from 1 to 10. | 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months | |
Secondary | Exercise Self-Efficacy Scale | This will be measured by the Exercise Self-Efficacy Scale, in which participants are asked how certain they are that they can get to perform an exercise routine regularly (three or more times a week). The scale ranges from 0 (not confident) to 100 (highly confident). | 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months | |
Secondary | Change in perception about exercise benefits and exercise barrier | It will be measured with a self-reported questionnaire. For the exercise benefits, the scale range as "strongly disagree, disagree, agree, strongly agree". For the exercise barriers the scale range as "sometimes a barrier", "often a barrier" |
5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months | |
Secondary | Modified Canadian Aerobic Fitness test | mCAFT is a graded step test and can predict VO2peak using a regression equation recently published. Thus, we are confident that we will get usable data for each person and as we are looking for a proportion of people who change over time, persons who do not achieve a peak and have low values on the mCAFT will have a very low value for exercise capacity. Greater steps cadence imply on greater oxygen cost |
3 timepoints: 3 month, 6 month and 18 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |